Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 6, 1996

View Archived Issues

New analgesic compounds with novel mechanism of action disclosed by Novo Nordisk

Anti-E-selectin antisense compound from Isis inhibits mRNA splicing

ChemGenics/Wyeth-Ayerst antibacterial drug discovery collaboration

Cytovene approved for new indication in U.S.

Connective Therapeutics acquires rheumatoid arthritis Rx from SKB

PAI-1 diagnostic approved for marketing in U.S.

Successful pivotal Mexican trial for oral impotency therapy

Varian, University of Arizona collaborate on methods of enhancing gene therapy efficacy

FDA tentatively approves generic NSAID

SKB, IDEC initiate phase III testing of antirheumatic antibody

Oncogene Science issued patent on gene transcription

Cytel to implement new development strategy for HBV vaccine

Etex signs marketing agreement for bone substitute

Sepracor gets go-ahead for U.S. clinical trials on (S)-oxybutynin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...